Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC. (HALO)
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2025
Reporting Period: Third quarter ended September 30, 2025
This filing serves as a notification of the Company's third-quarter financial results and a significant executive leadership transition.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the detailed financial results for the third quarter ended September 30, 2025. However, the text of this Form 8-K does not provide specific numerical values for:
- Revenue
- Net Profit or Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Positions
Note: Specific financial figures are not present in the provided text and must be sourced from the attached press release (Exhibit 99.1).
Material Changes and Corporate Events
Executive Departure
Nicole LaBrosse, Senior Vice President and Chief Financial Officer, has announced her departure to pursue a new professional opportunity.
- Transition Plan: Ms. LaBrosse will continue to serve as CFO until the earlier of the hiring of a new CFO or March 30, 2026.
- Search Status: The Company has initiated a search for a successor.
- Reason for Departure: The filing explicitly states the departure is not the result of any disagreement with independent auditors or the Company regarding financial statements, internal controls, operations, or policies.
- Agreement: The Company expects to enter into a transition and release agreement with Ms. LaBrosse.
Guidance, Outlook, and Risks
The provided text does not contain specific forward-looking guidance, updated financial outlook, or detailed risk factors beyond the standard disclosure regarding the CFO transition. The filing notes that the attached press release is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, earnings, and cash flow figures.
- Monitor future filings for the announcement of the new Chief Financial Officer.
- Verify the terms of the transition and release agreement with Ms. LaBrosse once executed.
- Confirm the Company's liquidity position given the upcoming leadership change in finance.